By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
SurvivorNet on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...
The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...
MedPage Today on MSN
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...
Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...
Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results